Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
Top Page
Agenus
(NASDAQ:AGEN)
38Underperform
Positive Factors
Efficacy in cancer treatment
BOT/BAL continues to show strong results across multiple MSS CRC settings.
Investor confidence
Longer follow-up response and survival data are likely to reinvigorate investor confidence in the de-risked nature of the upcoming confirmatory Ph. III study.
Negative Factors
Financial stability
Agenus' stock is experiencing weakness due to concerns over its prolonged cash runway.
Regulatory challenges
Securing an initial approval in the neoadjuvant setting could be a difficult path to market given the time needed for sufficient follow-up and safety compared to pursuing late-line CRC.
Agenus (AGEN) vs. S&P 500 (SPY)
Market Cap
$48.09M
Dividend YieldN/A
Average Volume (3M)393.50K
Price to Earnings (P/E)―
Beta (1Y)3.61
Revenue Growth59.00%
EPS Growth32.67%
CountryUS
Employees389
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.69
Shares Outstanding23,458,930
10 Day Avg. Volume434,213
30 Day Avg. Volume393,498
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.30
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside276.34% Upside
Rating ConsensusHold
Number of Analyst Covering4
Agenus Business Overview & Revenue Model
Company DescriptionAgenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
How the Company Makes MoneyAgenus makes money primarily through strategic partnerships, licensing agreements, and the development and commercialization of its proprietary immuno-oncology therapies. The company enters into collaborations with pharmaceutical and biotechnology firms to co-develop and co-commercialize its products, which often involve upfront payments, milestone payments, and royalties on sales. Additionally, Agenus may receive funding from grants and research collaborations, as well as revenue from the sale of its adjuvants and other immune-enhancing technologies. These partnerships and financial arrangements are critical to supporting its research and development activities and advancing its pipeline of cancer therapies.
Agenus Financial Statement Overview
Summary
Agenus faces substantial financial challenges, characterized by persistent losses, high leverage, and negative cash flows. While there is some revenue growth, it is insufficient to offset operational inefficiencies and financial instability. The company remains heavily reliant on external funding, and efforts to improve cash flow management are critical.Income Statement
Agenus shows a challenging financial trajectory with negative net income consistently over the years. The TTM (Trailing-Twelve-Months) reveals negative EBIT and EBITDA margins of -61.66% and -48.41%, respectively, indicating operational inefficiencies. Revenue growth is inconsistent, with recent growth compared to prior year, but still overshadowed by high operating losses.35
Negative
Balance Sheet
The balance sheet highlights a negative stockholders' equity, indicating financial distress and solvency issues. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio is also negative, reflecting more liabilities than assets. This scenario poses significant risks to financial stability.30
Negative
Cash Flow
Cash flow analysis shows significant negative operating and free cash flows, which are improving but remain concerning. Free cash flow growth is positive compared to previous periods, yet the company struggles to generate positive operating cash flow, indicating reliance on external financing.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 320.08M | 156.31M | 98.02M | 295.67M | 88.17M | 150.05M | Gross Profit |
| 131.99M | -81.37M | -99.23M | 113.59M | -56.80M | -18.29M | EBIT |
| 53.49M | -159.55M | -179.43M | 42.28M | -117.23M | -70.14M | EBITDA |
| 72.56M | -145.92M | -161.85M | 44.02M | -114.63M | -63.45M | Net Income Common Stockholders |
| -1.53M | -245.76M | -271.51M | -94.70M | -240.13M | -149.14M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 53.05M | 76.11M | 193.36M | 306.92M | 99.87M | 61.81M | Total Assets |
| 136.40M | 313.91M | 413.56M | 465.96M | 214.51M | 155.34M | Total Debt |
| 13.36M | 78.01M | 78.43M | 58.29M | 55.73M | 23.39M | Net Debt |
| -39.70M | 1.90M | -100.25M | -233.64M | -44.14M | -38.41M | Total Liabilities |
| 310.95M | 462.30M | 468.46M | 418.05M | 426.01M | 386.67M | Stockholders Equity |
| -172.47M | -160.33M | -61.28M | 34.44M | -203.67M | -225.36M |
| Cash Flow | Free Cash Flow | ||||
| -41.74M | -234.16M | -228.44M | -23.67M | -142.56M | -23.34M | Operating Cash Flow |
| 12.60M | -224.20M | -175.37M | 10.14M | -139.10M | -18.68M | Investing Cash Flow |
| -52.27M | 3.40M | -33.61M | -43.15M | -4.44M | -4.66M | Financing Cash Flow |
| 194.34M | 119.87M | 95.83M | 225.26M | 183.85M | 31.32M |
Agenus Technical Analysis
Negative
1.86
Price Trends
3.16
Negative
3.33
Negative
6.21
Negative
Market Momentum
-0.39
Positive
17.86
Positive
3.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGEN, the sentiment is Negative. The current price of 1.86 is below the 20-day moving average (MA) of 2.79, below the 50-day MA of 3.16, and below the 200-day MA of 6.21, indicating a bearish trend. The MACD of -0.39 indicates Positive momentum. The RSI at 17.86 is Positive, neither overbought nor oversold. The STOCH value of 3.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AGEN.
Agenus Risk Analysis
Agenus disclosed 84 risk factors in its most recent earnings report. Agenus reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Agenus Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $9.77B | 41.86 | 19.71% | ― | 52.97% | ― | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
47 Neutral | $2.07B | ― | -600.68% | ― | -98.62% | -86.21% | |
45 Neutral | $1.58B | ― | 18.68% | ― | 36.00% | 63.50% | |
44 Neutral | $114.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
43 Neutral | $1.41B | ― | -26.84% | ― | 1.99% | 15.95% | |
38 Underperform | $48.09M | ― | 260.68% | ― | 59.00% | 32.67% |
* Healthcare Sector Average
Performance Comparison
AGEN
Agenus
1.68
-10.31
-85.99%
ARWR
Arrowhead Pharmaceuticals
15.07
-12.35
-45.04%
BCRX
BioCryst
7.54
2.65
54.19%
CLDX
Celldex
20.14
-22.38
-52.63%
SRPT
Sarepta Therapeutics
98.37
-25.39
-20.52%
ADAP
Adaptimmune Therapeutics
0.45
-1.01
-69.18%
Agenus Earnings Call Summary
Earnings Call Date: Mar 11, 2025 | % Change Since: -13.49% | Next Earnings Date: May 13, 2025
Earnings Call Sentiment Positive
The earnings call highlighted Agenus' significant progress in reducing operational costs and promising clinical outcomes from BOT/BAL trials, garnering external validation. However, financial challenges such as a reduced cash balance and net loss, along with the temporary shelving of pipeline products, were noted. Nonetheless, the strategic plans to monetize assets and focus on high-potential programs indicate a forward-looking approach.Highlights
Significant Operational Burn Reduction
Agenus reduced its annualized operational burn to approximately $50 million by the middle of the year, aligning with their strategic cost reduction goals.
Promising Clinical Outcomes of BOT/BAL
BOT/BAL showed promising results in colorectal cancer, demonstrating durable responses and prolonged survival in refractory microsatellite stable colorectal cancer, offering potential revolutionary treatment options.
External Validation and Trials
Leading global oncology centers are independently conducting trials with BOT/BAL, reinforcing confidence in its potential benefits for patients.
Revenue Recognition
Agenus recognized revenue of $103.5 million for the year ended December 31, 2024.
Strategic Asset Monetization
Agenus is engaged in discussions for monetizing non-core assets, including its Emeryville manufacturing facility, to strengthen its financial position.
Lowlights
Reduced Cash Balance
The company ended the year with a cash balance of $40.4 million, down from $76.1 million the previous year.
Net Loss
Agenus incurred a net loss of $232.3 million or $10.59 per share for the year ended December 31, 2024.
Pipeline Products Put on Hold
Some pipeline products have been shelved temporarily due to the current market's lack of interest in immuno-oncology.
Company Guidance
In the recent earnings call, Agenus Inc. provided substantial guidance regarding its financial performance and strategic direction. The company reported a significant reduction in its annualized burn rate to approximately $50 million by mid-2025, aligning with its strategy to optimize resource allocation. Despite ending 2024 with a consolidated cash balance of $40.4 million, down from $76.1 million the previous year, Agenus remains committed to its revolutionary BOT/BAL program, which has demonstrated promising clinical outcomes in colorectal cancer. The company's revenue for 2024 was $103.5 million, with a net loss of $232.3 million or $10.59 per share. For Q4 2024, revenue stood at $26.8 million against a net loss of $46.8 million or $2.04 per share. Agenus is actively pursuing external partnerships and monetizing non-core assets to bolster its financial position while continuing to advance the BOT/BAL program, particularly in neoadjuvant settings for colorectal cancer.Agenus Corporate Events
Private Placements and FinancingBusiness Operations and Strategy
Agenus Secures $22M Mortgage to Advance Cancer Treatment
Positive
Nov 27, 2024
Agenus Inc. has secured a $22 million mortgage to bolster its cash reserves and support strategic operational realignment, focusing on its promising immunotherapy candidates, botensilimab and balstilimab, for colorectal cancer. The loan, facilitated by L&L Capital, involves a two-year term with interest payable in cash and stock. Agenus aims to significantly cut costs and transform its manufacturing operations while advancing its clinical programs, positioning itself for growth and innovation in cancer treatment.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.